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Abstract
Background: Multiple Sclerosis (MS) is a chronic inflammatory disease causing demyelination and nerve loss in the central
nervous system. Experimental autoimmune encephalomyelitis (EAE) is an animal model of MS that is widely used to
investigate complex pathogenic mechanisms. Transcriptional control through isoform selection and mRNA levels
determines pathway activation and ultimately susceptibility to disease.
Methodology/Principal Findings: We have studied the role of alternative splicing and differential expression in lymph node
cells from EAE-susceptible Dark Agouti (DA) and EAE-resistant Piebald Virol Glaxo.AV1 (PVG) inbred rat strains using
Affymetrix Gene Chip Rat Exon 1.0 ST Arrays. Comparing the two strains, we identified 11 differentially spliced and 206
differentially expressed genes at day 7 post-immunization, as well as 9 differentially spliced and 144 differentially expressed
genes upon autoantigen re-stimulation. Functional clustering and pathway analysis implicate genes for glycosylation,
lymphocyte activation, potassium channel activity and cellular differentiation in EAE susceptibility.
Conclusions/Significance: Our results demonstrate that alternative splicing occurs during complex disease and may govern
EAE susceptibility. Additionally, transcriptome analysis not only identified previously defined EAE pathways regulating the
immune system, but also novel mechanisms. Furthermore, several identified genes overlap known quantitative trait loci,
providing novel causative candidate targets governing EAE.
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Introduction
Multiple Sclerosis (MS) is a complex chronic inflammatory
disease primarily affecting young adults. Patients experience
deregulated inflammation in the periphery leading to the
generation of autoreactive cells that migrate to the target organ,
the central nervous system (CNS) [1]. The triggers and factors
determining the underlying pathogenic peripheral immune
response are unknown; however, modulation of the immune
system and lymphocyte trafficking both serve to perturb disease.
Use of general immunosuppressive drugs such as mitoxantrone,
depleting antibodies against B-cells or antibodies that prevent
CNS infiltration all reduce clinical disease [2,3,4]. Despite this,
secondary damage to neurons and axons causes a progressive
disability with no currently effective therapeutic options [5].
Myelin oligodendrocyte glycoprotein (MOG)-induced experi-
mental autoimmune encephalomyelitis (EAE) is an animal model
of MS with similarities in pathogenicity and histopathology [6].
Inbred rat strains differ in their susceptibility to disease, permitting
the study of susceptible genetic determinants and pathogenic
mechanisms that give insight into human MS. We previously
described the disease kinetics of EAE-susceptible Dark Agouti
(DA) and major histocompatibility complex (MHC)-identical but
EAE-resistant Piebald Virol Glaxo.AV1 (PVG) rats in peripheral
lymph nodes and the spinal cord [7]. We recorded differences in T
helper (TH) cell differentiation and regulation of inflammatory
markers in lymph nodes at day 7 post-EAE induction. We also
characterized effector functions following re-stimulation with
autoantigen. However, our previous work only focused on known
disease-associated pathways including TH1 [8] and TH17 [9].
Many studies suggest EAE susceptibility and disease mecha-
nisms are regulated at the level of transcription. Differential
expression of genes related to antigen processing and presentation
[10], chemokines, cytokines and apoptosis [11], as well as
extracellular matrix, cell adhesion molecules and molecules
involved in cell division, death and transcription [12], have all
been reported. Several of these pathways have also been identified
in MS [13,14,15]. Furthermore, alternative splicing of genes may
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result in altered function important for disease pathogenesis. The
MS associated interleukin-7 receptor (IL-7R) gene [16] is suspected
to be involved in MS etiology through the differential splicing of
membrane-bound and soluble forms [17]. However, genome-wide
investigation of alternative splicing in MS or EAE has not yet been
addressed.
In this study we carried out a well powered study of the EAE-
susceptible DA and EAE-resistant PVG strains using Affymetrix
GeneChip Rat Exon 1.0 ST Arrays to assess exon- and gene-level
expression differences in ex vivo and MOG re-stimulated lymph
node cells. We identify several genes that are alternatively spliced
between the strains and may govern disease-driving pathways. In
addition, we examine expression differences identifying novel
candidates and pathways that associate with disease induction and
effector phase functions. Furthermore, several of the genes overlap
known quantitative trait loci (QTLs), providing novel candidate
targets controlling EAE susceptibility.
Materials and Methods
Ethics Statement
All experiments in this study were approved and performed in
accordance with the guidelines from the Swedish National Board
for Laboratory Animals and the European Community Council
Directive (86/609/EEC) under the ethical permit N332/06
entitled ‘Genetic regulation, pathogenesis and therapy of EAE,
an animal model for multiple sclerosis’, which was approved by
the North Stockholm Animal Ethics Committee (Stockholms
norra djurfo¨rso¨ksetiska na¨mnd). Rats were tested according to a
health-monitoring program at the National Veterinary Institute
(Statens Veterina¨rmedicinska Anstalt, SVA) in Uppsala, Sweden.
Animals and EAE Induction
Inbred DA rats were originally obtained from the Zentralinstitut
fu¨r Versuchstierzucht (Hannover, Germany) and MHC-identical
PVG rats from Harlan UK Limited (Blackthorn, UK). Animals
were bred in the animal facility at Karolinska Hospital (Stockholm,
Sweden) in a pathogen-free and climate-controlled environment in
polystyrene cages containing aspen wood shavings with free access
to standard rodent chow and water with regulated 12-hour light/
dark cycles. MOG, amino acids 1-125 from the N terminus, was
expressed in Escherichia coli and purified to homogeneity by chelate
chromatography [18]. The purified protein, dissolved in 6M urea,
was dialyzed against phosphate buffered saline (PBS) to obtain a
physiological preparation that was stored at 220uC. Female rat’s
aged 10–12 weeks were anaesthetized with isoflurane (Forene,
Abbott Laboratories, Chicago, IL, USA) and injected subcutane-
ously in the tail base in order to induce EAE with a 200 ml
inoculum containing 15 mg MOG in PBS, emulsified 1:1 with
incomplete Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO,
USA).
Tissue Collection and Cell Culture
Animals were sacrificed using CO2 7 days post-EAE induction,
before debut of clinical disease signs. Draining inguinal lymph
nodes were collected and placed in DMEM (Gibco-BRL, Grand
Island, NY, USA) enriched with 5% fetal calf serum, 1% L-
glutamine, 1% penicillin-streptomycin, 1% pyruvic acid (all from
Life Technologies, Paisley, Scotland) and 50 mM 2-Mercaptoeth-
anol (‘complete media’; Gibco-BRL) before being mechanically
separated by passage through a mesh screen with the bolus of a
syringe. Cells were spun at 300 g, resuspended in complete media
and 206106 cells were plated in 10 cm Nunclon Delta Surface
Petri Dishes (Nunc, Roskilde, Denmark). Cultures were stimulated
for 24 hrs with 25 mg/ml of the encephalogenic MOG91–108
peptide (PPR, Downton, UK). Following stimulation the cultured
cells were resuspended, washed with PBS, spun and resuspended
in 1 ml of TRIzol (Invitrogen, Carlsband, CA, USA). Cells that
were not allocated to cell culture (greater than 126106) were
washed with PBS, spun and resuspended in 1 ml of TRIzol.
Samples were snap frozen in liquid nitrogen and stored at 270uC.
Flow Cytometry
Lymph node cells were washed with cold PBS and resuspended
in a further 100 ml of PBS. Cells were stained for 20 min at 4uC
with the following antibodies: CD3-APC, CD4-PE, CD8a-PE, and
CD45RA-PE:Cy5 (all from BD Biosciences, San Jose, CA, USA).
Staining was visualized on a FACS Calibur (BD, Franklin Lakes,
NJ, USA) with Cell Quest (version 3.2.1f1, BD) and analyzed using
FlowJo (version 8.8; Tree Star Inc., Ashland, Oregon).
Exon Sequencing
Genomic DNA was isolated using a standard protocol. PCR
was performed with primers surrounding differentially spliced
exons. The amplified products were run on a 1% agarose (Sigma-
Aldrich) electrophoresis gel. Bands were extracted and purified
using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA,
USA). Sequencing reactions were done at MWG (Ebersberg,
Germany). Alignment was performed in Vector NTI Advance
v.10 (Invitrogen).
Quantitative Real-Time PCR
Lymph node ex vivo or in vitro stimulated cells were washed with
PBS before being resuspended in RLT buffer (Qiagen). RNA was
purified using an RNeasy kit (Qiagen) and cDNA subsequently
prepared using the iScript kit (Bio-Rad, Hercules, CA, USA).
Quantitative real-time PCR (qPCR) was performed using a
BioRad iQ5 iCycler Detection System with a two-step PCR
protocol (95uC for 10 min followed by 40 cycles of 95uC for 10 sec
and 60uC for 30 sec), using SYBR Green (Bio-Rad) as the
fluorophore. Relative expression levels, corrected for amplification
efficiency, were analyzed using iQ5 v2.0 software (BioRad). The
primers used for SYBR Green reactions are listed in Table S1.
Mann-Whitney non-parametric tests were performed using
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).
RNA Extraction and Array Hybridization
Total RNA was extracted using TRIzol reagent, and further
purified and DNase I treated using an RNeasy Mini kit (Qiagen)
and RNase-Free DNase Set (Qiagen), according to the manufac-
turer protocols. RNA concentration and purity was determined
through measurement of A260/A280 ratios with a NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE, USA). Confirmation of RNA quality was assessed using
the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA). RNA samples were immediately frozen and stored at
280uC. 1 mg of total RNA was used for each sample. Target
labeling, as well as array hybridization, washing and staining were
performed as described in the GeneChip Whole Transcript (WT)
Sense Target Labeling manual (http://www.affymetrix.com).
Arrays were scanned using the GeneChip Scanner 3000 7G
(Affymetrix).
Data Analysis
The microarray data is available in MIAME-compliant (mini-
mum information about a microarray experiment) format at the
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) [19]
Exon and Gene Profiling of EAE
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under accession code E-MEXP-2237. CEL intensity files were
produced using GeneChip Operating Software version 1.4
(Affymetrix) and quality tested using the Affymetrix Expression
Console. All 16 files were deemed suitable for further study. Probe-
level data were normalized using Robust Multi-array Average
(RMA) [20]. Detection of alternative splicing events was performed
using three parallel approaches: 1) Calculations of Microarray
Detection of Alternative Splicing (MiDAS; Alternative Transcript
Analysis Methods for Exon Arrays; Affymetrix-White-Paper); 2)
Rank Product of Splice Index [21] (100 permutations) were
performed in R v2.6.2 with the Bioconductor v2.4 [22] package
OneChannelGUI v1.4.5 [23]; 3) An Alternative Splice ANOVA
model implemented in Partek Genomics Suite v6.4 (Partek
Incorporated, St.Louis, MO, USA) together with a filter to select
for probe-sets showing significant alternative splicing score,
determined at a 5% False Discovery Rate (FDR) [24], and no
differential expression at gene level (transcript p.0.05). Transcripts
that were significant from all three approaches were visually
inspected in the Partek’s Gene View to generate lists of alternative
splicing candidates. Detection of differential expression at the gene
level was performed in Partek Genomics Suite 6.4 (Partek
Incorporated). Data was summarized at the gene level using a
One-Step Tukey’s Biweight Algorithm, which reduces the effect of
outlier probe-sets (Statistical Algorithms Description Document;
Affymetrix-White-Paper). An ANOVA model, using strain, condi-
tion and batch as co-factors, was used to generate raw p values,
while FDR was used for multiple test corrections. Genes with 5%
FDR were classified as differentially expressed.
Functional Association Analysis
The lists of differentially expressed genes were uploaded into The
Database for Annotation, Visualization and Integrated Discovery
v6 (DAVID; http://david.abcc.ncifcrf.gov/) [25,26] to determine
differentially regulated pathways using the full rat genome as
reference background. Data were analyzed in the ‘‘Functional
Annotation Clustering’’ tool using the ‘‘High’’ classification
stringency setting for Molecular Function (MF) and Biological
Process (BP) Gene Ontology (GO) terms. Functional annotation
clusters with enrichment scores.1.3 were considered significant, in
accordance with DAVID recommendations [26]. Pathway analysis
was also performed using non-parametric Gene Set Enrichment
Analysis (GSEA), v.2 [27]. GSEA considers and ranks all genes in an
experiment (not only those above an arbitrary cutoff). It then tests if
the list of ranked genes is significantly enriched for pre-defined
groups of genes, or ‘‘gene sets’’. For these analysis 1191 gene sets
were used, which comprise the entire C5/GO gene sets collection of
MSigDB version 2.5 [27], plus a subset of the C2/curated gene sets
collection. For the latter, gene sets from the following contributors
were used: Biocarta, GO, GenMAPP, KEGG, Sigma-Aldrich,
Signaling transduction KE and Signaling Alliance. GSEA was run
with default settings (1000 gene set permutations). Gene sets with
5% FDR were considered significant in accordance with GSEA
recommendations (GSEA user guide; http://www.broad.mit.edu/
gsea/doc/GSEAUserGuideFrame.html).
Results
Experimental Design
DA and PVG rats were immunized with MOG to induce EAE.
MHC-identical rat strains were used in order to investigate the
role of non-MHC influences in alternative splicing and
differential expression during EAE. After 7 days of the
autoimmune response inguinal lymph nodes were extracted from
4 animals of each strain. Lymph node cells were divided into two
conditions: (i) direct ex vivo and (ii) MOG re-stimulation (Figure 1).
No differences between strains in lymphocyte types (CD3+,
CD4+, CD8+ T cells or CD45RA+ B cells) were detected using
flow cytometry (Figure 2). The day 7 ex vivo cells represent an
early disease stage when the immune response towards antigen
has been mounted in the draining lymph node, but before
leukocyte infiltration into the CNS and clinical signs are evident.
MOG re-stimulation mimics the encounter between autoreactive
cells and their target in the CNS, where effector molecules such
as interferon-c (IFN-c), interleukin-17 (IL-17) and IL-22 become
up-regulated [7].
Alternative Splicing between Susceptible and Resistant
Strains in EAE
We investigated the role that alternative splicing plays in EAE
induction and susceptibility using three parallel analytic approach-
es: MiDAS, Rank Product of the Splice Index and an Alternative
Splicing ANOVA, followed by visual filtering. We first compared
exon expression from the DA vs. PVG day 7 ex vivo conditions. 11
candidate genes for alternative splicing were identified (Table 1;
Figure S1). We used the Ensembl (http://www.ensembl.org) and
Interpro (http://www.ebi.ac.uk/interpro) databases to evaluate if
Figure 1. Experimental design. DA (n = 4) and PVG (n = 4) female
rats were immunized with MOG (day 0) to induce EAE. At day 7, before
clinical symptoms, lymph nodes were extracted and either directly
harvested (ex vivo) or stimulated with autoantigen (MOG re-stimulated).
cRNA was prepared and gene expression tested using 16 Affymetrix Rat
Exon 1.0 ST Arrays.
doi:10.1371/journal.pone.0007773.g001
Figure 2. Cell types from lymph nodes 7 days after immuni-
zation. DA (n = 4) and PVG (n = 4) have equivalent proportions of CD3+
T cells as well as the CD4+ and CD8+ subsets, in addition to equal
CD45RA+ B cells. Error bars represent standard deviation.
doi:10.1371/journal.pone.0007773.g002
Exon and Gene Profiling of EAE
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the alternate isoforms may lack important protein functions. The
isoforms for 9 of the 11 genes had putative altered protein
function. The alternative splicing analysis was confirmed and
quantified between strains using qPCR with primers designed for
specific isoforms of each candidate (Figure 3). Itpr2 isoforms were
constitutively expressed for each strain in naı¨ve and immunized
lymph node cells (Figure 3A) while all other candidates except
Ddx19a displayed EAE-specific regulation, as naı¨ve lymph node
cells did not display the same isoform expression patterns.
We next tested if alternative splicing was involved after MOG
re-stimulation, which mimics the autoantigen re-encounter that
occurs when autoreactive cells migrate to the CNS. We compared
DA vs. PVG MOG re-stimulated exon expression and identified 9
alternatively spliced genes; 3 of which (Usf1, Tmem41B and
Slc24a6) were MOG-re-stimulation specific (Table 2; Figure S2).
We confirmed the Affymetrix results using qPCR for each of the
candidate genes (Figure 3). The isoforms for 6 of the 9 genes had
putative altered protein function. We then compared the two
strains individually (i.e. ex vivo vs. MOG re-stimulated for DA and
PVG separately). We identified a single alternatively spliced gene
between DA conditions, the acetylcholine receptor e subunit
(Chrne; p = 7.77E-11; Figure S3A). The last 2 exons at the 39 end
were reduced after re-stimulation and would result in the loss of
the signaling peptide. A single alternatively spliced gene was
identified when comparing PVG conditions, the cAMP response
element modulator (Crem; p = 1.95E-06; Figure S3B). The first 2
exons at the 59 end were reduced after re-stimulation although no
specific domain is associated with this portion of the gene.
Mismatches between a microarray probe and its target sequence
affect hybridization that cause erroneous probe signal estimates
[28]. To determine if genetic differences (single nucleotide
polymorphisms for instance) have affected our alternative splicing
detection rates, we sequenced the exons of 4 genes that were
alternatively spliced in both ex vivo and re-stimulated conditions.
No genetic variation was discovered in Itpr2, Nsmaf and Cpsf3l (data
not included). However, a SNP was found in probe-set 5733439 of
Ddx19a exon 10, which could affect intensity values (Figure S4A).
Accordingly, we could not reproduce the Ddx19a exon 10
Affymetrix data using qPCR (Figure S4B).
Differential Expression and Pathway Regulation between
Susceptible and Resistant Strains
To assess EAE-relevant genes we compared day 7 ex vivo
expression between EAE-susceptible DA and EAE-resistant PVG
rats. At a 5% FDR cut-off margin 206 transcripts were differentially
expressed (Table S2). DAVID clustering analysis identified five
biological pathways that were significantly affected during early
EAE stages: glycosylation, apoptosis, synaptic transmission, extra-
cellular structure organization and cellular differentiation (Table 3).
GSEA identified a single functional gene set, sulfotransferase
activity, which was enriched in PVG ex vivo lymphocytes after
correcting for multiple hypothesis testing (Table 4). Interestingly,
two additional gene sets that fell just short of the significance
threshold were also positively associated with PVG ex vivo
lymphocytes. They contained genes involved in neuroactive
ligand-receptor interaction and substrate specific channel activity.
In vitro MOG re-stimulation of autoreactive cells from
peripheral lymphoid tissue replicates the pathogenic reaction
occurring in the CNS of affected rats and results in the up-
regulation of disease-driving effector molecules. Comparing the
two strains for expression differences after MOG re-stimulation,
144 genes were significant using 5% FDR (Table S3). DAVID
clustering analysis identified 8 biological pathways that were
regulated between the two strains upon MOG re-stimulation,
including T cell activation, apoptosis and transport (Table 5). In
addition, GSEA analysis highlighted that PVG cells up-regulated
of a range of potassium channel genes (Table 4).
We next examined genes that were differentially expressed upon
autoantigen re-stimulation for each strain separately. Comparing
DA day 7 ex vivo versus DA MOG re-stimulated conditions, 903
genes showed differential expression using 5% FDR (Table S4),
while the same comparison for PVG identified 1356 differentially
Table 1. Alternatively spliced genes between DA and PVG rats in day 7 ex vivo lymph nodes.
Ensembl ID Transcript ID Gene Symbol p-value Differential Exon Reduced Strain Interpro Domain Domain Function
T00000032767 7271202 Itpr2 7.01E-26 15 PVG - No specific domain
T00000017813 7354298 Nab1 4.14E-17 3 PVG IPR006986 Nab1, negative regulation of
transcription
T00000014289 7283429 Nsmaf 2.99E-13 12 DA IPR000409 Beige/Beach, unknown
T00000005280 7112632 Tor1aip1 9.72E-12 2 DA IPR008662 Lamina-assoc polypeptide
1C, membrane attachment
T00000009517 7248004 P-Rex1 1.64E-11 34 DA IPR001849 Pleckstrin homology,
intracellular signaling
T00000040922 7173094 Rock1 5.90E-10 12 PVG IPR011009 Protein kinase-like,
phosphotransfer
T00000036931 7198657 Dnttip2 1.99E-09 2 DA - Coil, coil domain
T00000026725 7282342 Cpsf3l 2.00E-09 5 PVG IPR001279 Beta-lactamase-like,
hydrolase
T00000059034 7185469 Ddx19a 1.51E-07 10 DA - No specific domain
T00000046251 7201908 Rasa1 3.17E-07 2 and 3 PVG IPR001936 Ras GTPase-activating
protein, signaling
T00000019338 7056128 Btbd10 2.34E-06 5 PVG IPR003131 Potassium channel, voltage
dependent
Differential Exon - alternatively spliced between strains; Reduced Strain - lower expression of indicated exon;
Interpro Domain - protein domain encoded in alternatively spliced exon.
doi:10.1371/journal.pone.0007773.t001
Exon and Gene Profiling of EAE
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Figure 3. Quantitative PCR confirmation of alternative splicing identified constitutive and EAE-specific isoforms. Relative expression
compared to Hprt from DA (n = 4) and PVG (n = 4) naı¨ve (A–E and I–M), day 7 post-immunization (A–E and I–M) and MOG re-stimulated (A–H)
conditions for selected target exons of alternatively spliced candidate genes. Itpr2 had constitutive isoforms while all other genes displayed EAE-
specific regulation. Dnttip exon 1 was not determined due to technical issues. * p,0.05 using a Mann-Whitney non-parametric test. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0007773.g003
Exon and Gene Profiling of EAE
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expressed genes (Table S5). DAVID clustering analyses revealed
that similar GO pathways were regulated in both strains. Both DA
and PVG respond to stimulus by regulating metabolism, transport,
kinase activity, transcription and apoptosis, which ultimately
control the immune response (Tables S6 and S7). Although
similar pathways were regulated in both strains, some of the genes
associated with these clusters were strain specific. For example,
sterol metabolism was highly enriched when comparing day 7 ex
vivo versus MOG re-stimulated conditions for each strain
separately, with 16 common associated genes. However, Mvd,
Oprs1 and Hmgcs1 were identified only for DA, while Osbpl5 and
Ebp were differentially expressed only for PVG.
Candidate Genes for EAE QTLs
Several of the differentially expressed genes and an alternatively
spliced gene identified in this study overlap with known QTLs
between DA and PVG (Table 6). We confirmed the Affymetrix
data using qPCR for 4 of these targets: Il4ra, Klrc3, App and Mfsd4
(Figure 4). These genes can be considered as candidate genes
governing EAE susceptibility in these regions.
Discussion
We investigated the induction phase and autoreactive cell
effector functions during EAE between susceptible DA and
resistant PVG inbred rat strains using whole genome expression
profiling of peripheral lymphatic tissue. Our aim was to assess the
role of alternative splicing and to identify genes that were
responsible for susceptibility to the disease. We hypothesized that
alternative splicing, a mechanism that widely occurs between
tissues and across time [29], is an important mechanism involved
in disease regulation. Additionally, we sought to identify candidate
genes and pathways responsible for genetically-determined EAE
susceptibility, some of which may also regulate the human disease,
MS.
Our study identified a total of 13 alternative spliced genes
between susceptible and resistant strains. This result is likely an
underestimation of the true event number with many false-
negatives (Type II error) due to at least two reasons. Firstly, we
have used a mixed population of lymph node cells, which could
mask the contribution of individual cell type specific alternative
spicing. Secondly, we employed several methods to increase
stringency, as most of the alternative splicing detection methods
suffer from high false positive detection rates [30]. We observed
genes that were differentially spliced between EAE-susceptible and
-resistant rat strains during disease induction and effector phases.
When examining the missing exons we determined that the
isoforms for many genes are missing integral protein domains, thus
providing support that these differences functionally contribute to
disease susceptibility. The spliced genes are involved in several
Table 2. Alternatively spliced genes between DA and PVG cells after MOG re-stimulation.
Ensembl ID Transcript ID Gene Symbol p-value Differential Exon Reduced Strain Interpro Domain Domain Function
T00000032767 7271202 Itpr2 6.41E-42 15 PVG - No specific domain
T00000014289 7283429 Nsmaf 1.29E-18 12 DA IPR000409 Beige/Beach, unknown
T00000005811 7107800 Usf1 7.80E-13 7 PVG IPR001092 Basic Helix-Loop-Helix, DNA
binding + transcription
T00000040922 7173094 Rock1 6.34E-12 12 PVG IPR011009 Protein kinase-like,
phosphotransfer
T00000026725 7282342 Cpsf3l 5.18E-11 5 PVG IPR001279 Beta-lactamase-like,
hydrolase
T00000016224 7055841 Tmem41b 1.96E-09 6 DA - Transmembrane Helix
T00000059034 7185469 Ddx19a 2.79E-08 10 DA - No specific domain
T00000019338 7056128 Btbd10 3.32E-07 5 PVG IPR003131 Potassium channel, voltage
dependent
T00000001868 7102483 Slc24a6 4.44E-05 8 DA - No specific domain
Differential Exon - alternatively spliced between strains; Reduced Strain - lower expression of indicated exon;
Interpro Domain - protein domain encoded in alternatively spliced exon.
doi:10.1371/journal.pone.0007773.t002
Table 3. DAVID enriched GO terms of differentially expressed genes between DA and PVG for day 7 ex vivo lymph nodes.
Category Representative GO Term Genes Count/List Pop Hits/Total Fold Enrichment p-value
GO:BP GO:0030154,cell differentiation Nuak2, Agrn, Cd5, Nrp2, App, Il2ra, Actn1, Cstb, F2r,
Rps6ka2, Igf1r, Capn5, Apbb1, Anxa1, Zfp37,
18/83 1584/12762 1.75 2.21E-02
GO:BP GO:0006493,protein amino
acid O-linked glycosylation
Pomgnt1, Galnt11, Galnt10, 3/83 17/12762 27.13 5.21E-03
GO:BP GO:0042981,regulation of apoptosis Nuak2, Cd5, App, Igf1r, Il2ra, Actn1, Anxa1, F2r, Cstb, 9/83 525/12762 2.64 1.93E-02
GO:BP GO:0007268,synaptic transmission Gnai1, Vdac3, Agrn, Sv2b, App, Nsg1, Stx3, 8/83 446/12762 2.76 3.93E-02
GO:BP GO:0043062,extracellular structure
organization and biogenesis
Agrn, App, Apbb1, F2r, 4/83 98/12762 6.28 2.51E-02
GO:BP - Gene Ontology, Biological Process; p value - modified Fischer Exact Test.
doi:10.1371/journal.pone.0007773.t003
Exon and Gene Profiling of EAE
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general signaling and transcriptional regulatory mechanisms that
were identified in this study. Rasa1 and Rock1 alternative splicing
was EAE-specific and could control cell motility, proliferation and
differentiation through Ras and Rho GTPases respectively
[31,32]. Additionally, Nab1, Cpsf3l, Btbd10 and Usf1 all modulate
transcription [33,34,35,36]. However, further investigation is
required to determine the precise effect these different isoforms
have during EAE induction. Interestingly, 5 of the 10 genes
identified (this excludes Ddx19a, which could not be reproduced
likely due to a SNP affecting hybridization) as alternatively spliced
in day 7 lymph nodes were also spliced after MOG re-stimulation.
This result indicates that these isoforms are constitutive during
disease and may govern disease-driving mechanisms.
Expressional regulation is an important mechanism modulating
biological processes. Many genes are differentially expressed
during disease, providing markers of disease progression and
indications of pathways and mechanisms that are deregulated. We
identified 206 genes that were differentially expressed between the
two stains in day 7 post-immunization lymph nodes. Of those
genes, Cd5, Il18r1 and Il2ra are known encephalomyelitis
candidates [7,37,38]. All three are strongly up-regulated in DA
lymph nodes. Disease-driving regulated genes in EAE are often
related to the immune system and govern processes including
antigen processing, transcription, cytokines and cellular attraction,
adhesion, division and death. Our study supports this body of
evidence but also extends the findings to propose new candidates
governing autoimmunity that are implicated in glycosylation
(Pomgnt1, Galnt11 and Galnt10). Our study focused on the periphery
where protein glycosylation may affect receptor signaling and
thereby alter disease susceptibility [39]. Additionally, pathogenic
Table 4. GSEA enriched gene sets between DA and PVG.
NAME Top 10 genes Source SIZE NOM p-val FDR q-val
DA vs. PVG day 7 ex vivo significant pathways
SULFOTRANSFERASE_ACTIVITY Chst9, Chst7, Chst10, Chst13, Tpst1, Hs3st5,
Chst3, Chst5, Chst8, Chst4
GO 20 0 0.03662996
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION Ptger3, P2ry14, Gzma, Uts2R, Prl, Mtnr1a,
Ghsr, P2ry4, Grin2B, Htr1B
KEGG 205 0 0.0560383
SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY Kcna1, Cacng5, Kcnj15, Kcna4, Nmur2,
Kcnb2, Kcne2, P2rx3, Kcnk4, Scn2b
GO 131 0 0.07680687
DA vs. PVG MOG restimulation significant pathways
VOLTAGE_GATED_POTASSIUM_CHANNEL_ACTIVITY Kcnj4, Kcnj3, Kcnj1, Kcnip2, Kcna5, Kcnh1,
Kcnj10, Kcna2, Kcnc1, Kcnj15
GO 31 0 0.014385469
FEEDING_BEHAVIOR Mc4r, Npy, Ghrl, Htr2c, Lep, Npw, Mchr1,
Calr2, Hcrtr2, Ppyr1
GO 21 0 0.015389259
POTASSIUM_ION_TRANSPORT Kcnj4, Kcnj2, kcnj3, Kcnj1, Kcnj11, Kcnip2,
Kcna5, Kcnh1, Kcnj10, Kcnf1
GO 49 0 0.027649486
POTASSIUM_CHANNEL_ACTIVITY Kcnj4, Kcnj3, Kcnj1, Kcnip2, Kcna5, Kcnh1,
Kcnj10, Kcna2, Kcnc1, Kcnj15
GO 41 0 0.02914241
HORMONE_ACTIVITY Gh1, Npy, Ghrl, Igf1, Stc1, Cga, Nppb, Calcb,
Chgb, Pnoc
GO 36 0 0.029265244
GPCRDB_CLASS_A_RHODOPSIN_LIKE Nmur1, Gpr85, Chrm5, Gpr83, Drd2, Mc4r,
Fpr1, Gpr37, P2ry1, Grpr
GenMAPP 133 0 0.032977927
RESPONSE_TO_NUTRIENT_LEVELS Nuak2, Npy, Ghrl, Lep, Stc1, Sst, Cdkn2b, Alb GO 26 0.001677852 0.034934502
INTERMEDIATE_FILAMENT_CYTOSKELETON Gfap, Drd2, Nefl, Krt31, Pkp1, Upp2, Krt2 GO 18 0.001658375 0.036004912
VOLTAGE_GATED_POTASSIUM_CHANNEL_COMPLEX Kcnj4, Kcnj3, Kcnj1, Kcna5, Kcnh1, Kcna2,
Kcnc1, Kcnj8, Kcns1, Kcnn3
GO 35 0 0.03604953
RESPONSE_TO_EXTRACELLULAR_STIMULUS Nuak2, Npy, Ghrl, Lep, Stc1, Sst, Cdkn2b, Alb GO 28 0.001712329 0.03640272
STRUCTURAL_CONSTITUENT_OF_CYTOSKELETON Actl7a, Gfap, Nefl, Krt31, Sorbs3, Ppl, Des,
Actl7b, Mapt, Krt2
GO 42 0 0.036414582
INTERMEDIATE_FILAMENT Gfap, Drd2, Nefl, Krt31, Pkp1, Upp2, Krt2 GO 18 0.00172117 0.036638036
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION Nmur1, Prss1, Npffr2, Chrm5, Gpr83, Gh1,
Taar2, Drd2, Mc4R, Fpr1
KEGG 205 0 0.037446167
SYSTEM_PROCESS Nmur1, Omp, Six3, Gja3, Sspn, Pmp22,
Drd2, Npy, Nrl, Kcnj1
GO 441 0 0.038417198
HSA01430_CELL_COMMUNICATION Chad, Gja3, Krt35, Krt34, Ibsp, Krt25, Krt31,
Nes, Krt86, Krt40
KEGG 96 0 0.038440228
SYNAPTIC_TRANSMISSION Omp, Pmp22, Drd2, Npy, Ghrl, Kcnip1,
Htr2c, Pcdhb13, Pcdhb6, Htr1b
GO 151 0 0.038810864
NEUROLOGICAL_SYSTEM_PROCESS Nmur1, Omp, Six3, Gja3, Pmp22, Drd2, Npy,
Nrl, Ghrl, Kcnip1
GO 290 0 0.039604984
CARBOHYDRATE_TRANSPORT Gh1, Ppbp, Ednra, Slc2a5 GO 15 0.001675042 0.046175405
Top 10 genes – top 10 ranking genes belonging to a gene set; source – source for the gene set; size – number of genes in a gene set; NOM p-val – nominal p value; FDR
q-val – false discovery rate.
doi:10.1371/journal.pone.0007773.t004
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glycosylated antigens are generated during EAE and antibodies
against these targets perturb disease [40].
After MOG re-stimulation we identified 144 genes that were
differentially expressed between the two strains. One the genes
strongly up-regulated in DA lymph nodes was Havcr1/Tim1, which
was also increased in cerebrospinal fluid mononuclear cells of
patients with MS [41]. GSEA analysis identified up-regulation of
several members of the inward rectifier potassium channel family,
including Kcnj1 and Kcnj4, in PVG cells, suggesting that these
channels may play a protective role in EAE. Kcnj4 (or Kir2.3) has
recently been linked with protection against neurodegeneration in
a cell model of Parkinson’s disease [42], although its role in the
immune system is currently unknown. There is strong interest in
targeting potassium channels for MS therapy and several clinical
trials related to the therapeutic targeting of voltage-gated K+ (Kv)
channels in MS are ongoing [43]. These therapies will likely not
only target nervous tissue and conductance, but also lymphocyte
proliferation [44,45]. Additionally, Kv channels regulate immune
synapses in the periphery where antigen presentation occurs and
lymphocyte function is determined [46].
It should be noted that stringent criteria were used for all our
analysis. We chose this approach to simplify interpretation of the
data, reduce the occurrence of false positives and provide strong
novel EAE susceptibility candidates. Because of the stringent
criteria, we find that only a portion of the genes from our previous
study [7], which utilized qPCR methods, pass the 5% FDR cut-off,
including Il18r1, Il2ra and FoxP3. However, genes that do not pass
a FDR of 5% in this study, including Il17f, Il7r, Stat4 and Tnf, are
consistently differentially expressed at a lower threshold (p,0.05).
When examining known MS candidates we found that both ll7r
and Il2ra were confirmed as being differentially expressed between
DA and PVG in day 7 ex vivo lymph nodes (p = 0.04 and
Table 5. DAVID enriched GO terms of differentially expressed genes between DA and PVG for MOG re-stimulated cells.
Category Representative GO Term First 10 Genes
Count/
List
Pop Hits/
Total
Fold
Enrichment p-value
GO:BP GO:0051234,establishment of
localization
Drd2, Arfgap1, Camk2d, Atp10a, Cxcr4, P2rx4,
Trpm6, Tpo1, Slc27a1, Dirc2
25/76 2420/12762 1.73 4.77E-03
GO:BP GO:0012501,programmed cell death Cd2, Litaf, Nuak2, Cd5, App, Fgf2, Igf1r, Il2ra, Cxcr4, F2r 11/76 690/12762 2.68 6.88E-03
GO:BP GO:0006464,protein modification
process
Pigq, Nuak2, Pomgnt1, Art2b, Camk2d, St8sia1,
Cry2, Uhrf1, Insr, Atg7
19/76 1403/12762 2.27 1.03E-03
GO:BP GO:0030154,cell differentiation Litaf, Nuak2, Cd5, Nrp2, App, Il2ra, Sort1, Cxcr4,
F2r, Cd2
16/76 1584/12762 1.70 4.05E-02
GO:BP GO:0046649,lymphocyte activation Cd2, Cd5, Nbn, Il2ra, Cxcr4 4/76 105/12762 6.40 2.38E-02
GO:BP GO:0008152,metabolic process Drd2, Gfpt2, Cdo1, St8sia1, Cybrd1, Lmo7, Chst10,
Trpm6, Capn5, Khdrbs3
51/76 7051/12642 1.21 2.91E-02
GO:BP GO:0000902,cell morphogenesis Nrp2, App, Fgf2, Igf1r, Camk2d, Socs2, Atp10a, Cxcr4 8/76 468/127642 2.87 1.98E-02
GO:BP GO:0042110,T cell activation Cd2, Cd5, Il2ra, Cxcr4 4/76 105/12762 6.40 2.38E-02
GO:BP GO:0048856,anatomical structure
development
Drd2, Nrp2, App, Camk2d, Il2ra, Csrp1, Sort1,
Atp10a, Hsd11b1, Insr
19/76 1988/12762 1.60 3.69E-02
GO:BP - Gene Ontology, Biological Process; p value - modified Fischer Exact Test.
doi:10.1371/journal.pone.0007773.t005
Table 6. Candidate genes for EAE quantitative trait loci.
QTL Chromosome Position (Mb) Candidate Genes Related Publication
‘‘Eae31’’ 1 183.9–193.1 Il4ra, Acadsb
Unnamed 1 234.5–268 Lipa, Ifit1, Pdlim1, RGD1303232
’Eae24-27’’ 4 44–116.6 Scrn1, LOC681217, Gimap4, Reg3g, Tspan33, Chn2 Becanovic et al., 2003
Eae20 4 157–160.5 Slc6a12 Jagodic et al., 2005
Eae22 4 ,167 Klrc3 Jagodic et al., 2005
Unnamed 5 125.6–173 Dmrtb1, Spata6, Pomgnt1, Csf3r, Agrn, Acot7, Cpsf3l
’Eae16’’ 8 81.4–102.9 Lrrc, Plscr2
Eae18a 10 55.8–62.7 Plscr3, Zmynd15, Eno3, Cldn7, Kif1c Jagodic et al., 2004
Unnamed 11 20–70 App, Mx1, Retnlg, Cd200r1, Parp9, Dirc2
’Eae17’’ 13 39.6–55.4 Mfsd4, Nuak2, Pik3c2b, Chi2l1, Cfh, Cxcr4
Unnamed 14 0–26.4 Naaa, Slc4a4
Eae19 15 83.3–97.7 Lmo7, Spry2 Sheng et al., 2005
’Eae23’’ 17 36–66 Pols
QTLs in quotations or unnamed are based on personal communication; Genes - differentially expressed between DA and PVG in day 7 ex vivo lymph node cells; Genes -
differentially expressed in MOG re-stimulated cells; Genes - differentially expressed in both ex vivo and re-stimulated conditions; Genes - alternatively spliced.
doi:10.1371/journal.pone.0007773.t006
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p = 861025, respectively). We also determined differential expres-
sion of Evi5 (p = 0.03) in ex vivo cells and Irf8/Icsbp1 (p = 0.02)
following MOG re-stimulation [47,48]. These results provide
further evidence that MOG-induced EAE in DA rats is a relevant
model for study of MS. However, not all MS candidate molecules
are transcriptionally regulated at this time-point in this tissue.
Candidate genes including KIF1b [49], RPL5 [50], IRF5 [47],
CD226 [51], CD6 and TNFRSF1A [48] were equally expressed
between susceptible and resistant strains.
Several studies have employed linkage analysis with QTL
mapping to identify genomic regions regulating EAE in rats
[52,53,54,55,56]. However, identification of the genetic polymor-
phisms responsible for disease susceptibility has been a slow
process. We combined QTL mapping and expression profiling, a
strategy that has been successful at identifying the molecular basis
of a number of QTLs in rats [57,58,59,60]. We have identified
numerous differentially expressed and alternatively spliced genes
overlapping previously described QTLs for EAE between DA and
PVG and confirmed several of them using qPCR. One candidate
from our study, Cxcr4, is involved in leukocyte trafficking and has
previously been implicated in EAE [61]. Another candidate, Klrc3,
encodes an activating natural killer (NK) cell receptor, which could
potentially regulate NK cell involvement in EAE [62,63]. We
propose these and other genes as candidates in the respective
genetic regions and believe that directed study will help identify
pathways regulated during autoimmune reactions, giving further
insight into human MS.
Supporting Information
Figure S1 Eleven genes alternatively spliced between DA and
PVG day 7 ex vivo lymph node cells, as presented from Partek’s
gene viewer (A-K). The average RMA normalized intensity values
and standard error for each probe-set, are shown for EAE-
susceptible DA (blue) and EAE-resistant PVG (red) rat strains. The
Log2 intensity scale is shown on the right axis. Arrows designate
alternatively spliced exons.
Found at: doi:10.1371/journal.pone.0007773.s001 (1.72 MB
PDF)
Figure S2 Nine genes alternatively spliced between DA and
PVG MOG re-stimulated lymph node cells, as presented from
Partek’s gene viewer (A–I). The average RMA normalized
intensity values and standard error for each probe-set are shown
for EAE-susceptible DA (blue) and EAE-resistant PVG (red) rat
strains. The Log2 intensity scale is shown on the right-had
axis.Arrows designate alternatively spliced exons.
Found at: doi:10.1371/journal.pone.0007773.s002 (1.05 MB
PDF)
Figure S3 Alternative splicing genes from ex vivo vs. re-
stimulated conditions, as represented from Partek’s gene viewer.
DA shows down-regulation of the 39 end of Chrne after MOG re-
stimulation (A). PVG shows down-regulation of the 59 end of
Crem after re-stimulation (B). The average RMA normalized
intensity values and standard error for each probe-set are shown.
Arrows designate alternatively spliced exons.
Found at: doi:10.1371/journal.pone.0007773.s003 (0.54 MB
PDF)
Figure S4 Ddx19a is an example of an alternatively spliced false-
positive induced by a SNP. (A) Sequencing exon 10 of Ddx19a
identified a SNP (arrows) in probe-set 5733439 between DA and
PVG. (B) Relative expression compared to Hprt for Ddx19a
determined no difference between DA (n = 4) and PVG (n = 4) for
exon 10, the putative alternatively spliced exon. Error bars
represent standard deviation.
Found at: doi:10.1371/journal.pone.0007773.s004 (0.28 MB
PDF)
Table S1 Primer sequences for SYBR quantitative real-time
PCR targets.
Found at: doi:10.1371/journal.pone.0007773.s005 (0.02 MB
XLS)
Table S2 Differentially regulated transcripts between DA and
PVG in day 7 ex vivo lymph nodes. 138 transcripts were
upregulated and 68 downregulated using DA as reference at a
5% FDR cut-off margin.
Found at: doi:10.1371/journal.pone.0007773.s006 (0.04 MB
XLS)
Table S3 Differentially regulated transcripts between DA and
PVG in MOG re-stimulated cells. 90 transcripts were upregulated
and 54 downregulated using DA as reference at a 5% FDR cut-off
margin.
Found at: doi:10.1371/journal.pone.0007773.s007 (0.04 MB
XLS)
Table S4 Differentially regulated transcripts comparing DA day
7 ex vivo and MOG re-stimulated conditions. 470 transcripts were
upregulated and 433 downregulated using day 7 ex vivo as
reference at a 5% FDR cut-off margin.
Found at: doi:10.1371/journal.pone.0007773.s008 (0.13 MB
XLS)
Table S5 Differentially regulated transcripts comparing PVG
day 7 ex vivo and MOG re-stimulated conditions. 637 transcripts
were upregulated and 719 downregulated using day 7 ex vivo as
reference at a 5% FDR cut-off margin.
Found at: doi:10.1371/journal.pone.0007773.s009 (0.18 MB
XLS)
Table S6 DAVID functional clustering results of DA day 7 ex
vivo and DA MOG re-stimulated conditions.
Found at: doi:10.1371/journal.pone.0007773.s010 (0.02 MB
XLS)
Table S7 DAVID functional clustering results of PVG day 7 ex
vivo and PVG MOG re-stimulated conditions.
Found at: doi:10.1371/journal.pone.0007773.s011 (0.03 MB
XLS)
Figure 4. Quantitative PCR confirmation of candidate genes for
EAE QTLs. Relative expression compared to Hprt of Klrc3, App, Mfsd4
and Il4ra from DA (n = 4) and PVG (n = 4) female rat lymph nodes, 7 days
post-immunization. DA lymph nodes had higher expression of all 4
targets, confirming the Affymetrix data. * p,0.05 using a Mann-
Whitney non-parametric test. Error bars represent standard deviation.
doi:10.1371/journal.pone.0007773.g004
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